Boardroom Alpha
Meeting calendar
BLCO · Annual meeting · Wednesday, May 20, 2026

Bausch & Lomb Corp

10 nominees · 4 ballot items.

Election of ten directors; advisory vote to approve named executive officer compensation; approval to amend and restate the 2022 Omnibus Incentive Plan to add 25,000,000 shares; appointment of PricewaterhouseCoopers LLP as auditor and authorization for Board to fix remuneration.

Market cap
$5.8B
1Y TSR
+15.3%
Board grade
C
Record date
Mar 23, 2026
Filing
DEF 14A
Meeting concluded · May 20, 2026

Follow how the vote landed and what changed on Bausch & Lomb Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot4

  1. 1

    Election of Directors

    ManagementBoard: FOR

    Elect ten director nominees to serve until the 2027 Annual Meeting.

  2. 2

    Advisory Vote on Executive Compensation

    ManagementBoard: FOR

    Non-binding advisory vote to approve compensation of the named executive officers as disclosed in the proxy statement.

    More detail

    Proposal asks shareholders to cast a non-binding advisory vote to approve the disclosed compensation for named executive officers (NEOs). Management seeks endorsement to validate their pay-for-performance philosophy, which ties a significant portion of NEO pay to financial and strategic targets, uses independent compensation consultants, and includes governance features like clawback policies, share ownership guidelines, performance-based equity, and capped payouts. The advisory vote is used to gauge shareholder sentiment; while nonbinding, the Board and Talent and Compensation Committee will consider results when designing future programs. Key context includes strong prior say-on-pay support (~97% in 2025) and detailed disclosure of AIP, PSUs, RSUs, and CEO employment terms. The Board recommends a vote FOR, arguing the program aligns management and shareholder interests and reflects shareholder engagement and best practices.

  3. 3

    Amendment and Restatement of the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan

    ManagementBoard: FOR

    Approve increasing the Omnibus Plan share reserve by 25,000,000 common shares (to 77,000,000) to support future equity awards.

    More detail

    The proposal requests shareholder approval to amend and restate the Omnibus Incentive Plan to add 25 million shares to the reserve, increasing the authorized pool to 77 million shares (plus converted awards). Management seeks the increase to preserve ongoing equity grant practices necessary for attracting and retaining talent, to support long-term incentive programs including PSUs, RSUs and options, and to avoid replacing equity with cash which could misalign interests with shareholders. The board’s recommendation is based on analysis of anticipated grant needs, historical burn rate, overhang, and advice from an independent compensation consultant. Approving the increase would raise the overhang from ~12.7% to ~19.7% on a fully-diluted basis (as of Dec 31, 2025), which management characterizes as reasonable dilution to maintain competitive compensation. The plan contains customary governance limits (insider caps, non-employee director caps, no repricing without shareholder approval), transfer restrictions, anti-hedging, and clawback provisions. If not approved, the company may exhaust its reserve and face competitive disadvantages in equity-based talent retention and attraction. The Board recommends a vote FOR.

  4. 4

    Appointment of Auditor and Authorization of Board to Fix Remuneration

    ManagementBoard: FOR

    Appoint PricewaterhouseCoopers LLP as auditor for 2026 and authorize the Board to set PwC’s remuneration.

Director elections

Nominees on the ballot10

Independent
Tenure on this board
0.5 yrs
Also a director at
Elevance Health Inc (ELV)
Independent
Tenure on this board
4.2 yrs
Also a director at
Bausch Health Companies Inc (BHC)
Independent
Tenure on this board
2.4 yrs
Also a director at
Irhythm Holdings Inc (IRTC)
Independent
Tenure on this board
4.2 yrs
Also a director at
Acadian Asset Management Inc (AAMI)Bausch Health Companies Inc (BHC)
Brenton L. Saunders
Not independent
Tenure on this board
New nominee
Ownership

Top institutional holders10

Latest 13F quarter
1DEUTSCHE BANK AG\1.0%3,528,441$56M
2ICAHN CARL CActivist1.0%3,500,000$56M
3OAKTREE CAPITAL MANAGEMENT LPActivist0.9%3,382,739$54M
4GOLDENTREE ASSET MANAGEMENT LP0.7%2,660,508$42M
5D. E. Shaw Co., Inc.Activist0.7%2,607,000$41M
6Silver Point Capital L.P.0.6%2,245,000$36M
7DAVIDSON KEMPNER CAPITAL MANAGEMENT LP0.6%2,199,172$35M
8CASPIAN CAPITAL LP0.6%1,999,043$32M
9GLENVIEW CAPITAL MANAGEMENT, LLC0.5%1,910,496$30M
10NOMURA HOLDINGS INC0.4%1,256,181$20M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Bausch & Lomb Corp 2026 annual meeting?
Bausch & Lomb Corp (BLCO) holds its 2026 annual shareholder meeting on Wednesday, May 20, 2026.
What is the record date for the Bausch & Lomb Corp 2026 meeting?
The record date for the Bausch & Lomb Corp 2026 meeting is Monday, March 23, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Bausch & Lomb Corp's 2026 meeting?
The board is presenting 10 director nominees at the Bausch & Lomb Corp 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Bausch & Lomb Corp 2026 meeting?
Shareholders will vote on 4 proposals at the Bausch & Lomb Corp 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer